PT-141 Pen

Origin & Classification

PT-141 (bremelanotide) is a cyclic heptapeptide derivative of alpha-melanocyte-stimulating hormone with modifications including a lactam bridge to stabilize its conformation. It is synthesized using solid-phase peptide synthesis and belongs to the class of melanocortin receptor agonists. PT-141 differs from alpha-MSH in sequence and structural stability, conferring distinct receptor selectivity and potency.

Mechanism & Research Context

PT-141 interacts primarily with melanocortin 3 and 4 receptors (MC3R and MC4R), which are expressed in the central nervous system and are involved in regulation of appetite, sexual arousal, and energy homeostasis. Activation of these G protein-coupled receptors increases cAMP production and activates downstream signaling cascades. Researchers utilize PT-141 to study hypothalamic control of neuroendocrine functions, including modulation of gonadotropin release, sexual behavior, and energy balance. Studies explore interactions with dopaminergic and serotonergic systems, as well as cross-talk with pathways regulated by nitric oxide and oxytocin. The peptide serves as a tool for understanding the integrative physiology of melanocortin signaling.

Composition & Quality

PT-141 is supplied as a compounded, ready-to-use solution with purity typically exceeding 95 % as assessed by HPLC and mass spectrometry. Manufacturing under GMP-aligned conditions includes cyclic peptide synthesis, purification, and sterile filtration. Quality control includes verification of cyclization, peptide content, and absence of contaminants such as endotoxin. The compounded solution should be stored refrigerated per provided guidelines. Certificates of analysis accompany each batch, detailing sequence, purity, and storage recommendations.

Summary & Unified Disclaimer

This description summarizes the scientific context of the molecule. It is provided for educational and research discussion purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and no medical or consumption claims are made.